Market News AIOpen the app

Kestra Medical Technologies shared the main findings from the ACE-PAS study, showing its wearable defibrillator works well and is safe.

TrialRead the original at globenewswire.com
Good for KMTS

Kestra's published study found its ASSURE system met safety and effectiveness goals, including 100% success for analyzable heart rhythm shock events. Risk lasted beyond the first month, pointing to continued need for protection rather than a problem with the system.

KMTS · Kestra Medical Technologies, Ltd.

AI read · Good for KMTS

The AI's read

The published results add real-world support for the ASSURE system. The study also found that heart rhythm danger can last beyond the first month, pointing to continued need for protection rather than a failure of the system.

Get alerts for KMTS

Follow Kestra Medical Technologies, Ltd. (KMTS) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for KMTS
Free on the App Store and Google Play, or on the web.